Mustafa Özdoğan, MD· @ozdogan_md · X·· 15 小时前评分70
正文 · 原文
STATISTICALLY POSITIVE. CLINICALLY THIN.
KEYNOTE-B49: pembrolizumab + chemo delivered just +0.7 months median PFS in PD-L1 CPS≥1 HR+/HER2− advanced breast cancer with no OS benefit.
Significance ≠ meaningful benefit.
@hoperugo #ESMO26
106 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Mustafa Özdoğan, MD · x.com